<DOC>
	<DOCNO>NCT01188512</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity new live attenuate vaccine whooping-cough . It phase1 , single centre , dose-escalating , placebo-controlled study genetically modify B. pertussis strain give single intranasal dose healthy adult male volunteer . Effective vaccine need protect young infant ( 0 6 month , today vulnerable age group ) , preferably single administration early life . The successful outcome project would constitute important milestone towards nasal vaccination infant , possibly birth novel , single-dose pertussis vaccine . Our ultimate aim protect infant vulnerable age group , regular vaccination schedule use already available vaccine apply . The ultimate aim thus replace current vaccination schedule available vaccine , add first nasal vaccination protect early life .</brief_summary>
	<brief_title>First Adult Safety Trial Nasal Live Attenuated B. Pertussis Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<criteria>Subject include study meet follow criterion : Healthy male born 1979 1991 experience clinical pertussis ( lab . Verified ) past 10 year vaccinated pertussis vaccine . Informed consent form sign subject . Subject shall able attend schedule visit understand comply study procedure ( e.g . able read write Swedish ) . If follow criterion meet , subject must include study : Individuals pertussis toxin serum IgG antibodies ≥20 units/mL . Blood pressure rest ≥ 150/90 mmHg . Heart rate rest ≥80 bpm . Respiratory rate rest ≥ 20/minute . Unwillingness refrain use nicotine product screen day 28 . Use narcotic drugs/alcohol and/or history previous use drug/alcohol abuse whitin past 2 year prior screen The subject donate blood suffer blood loss least 450 ml ( 1 unit blood ) within 60 day prior screen donate plasma within 14 day prior screen . Receipt immunoglobulin , blood derive product , systemic corticosteroid immunosuppressant drug within 90 day prior day 0 . Use corticosteroids respiratory tract ( e.g . nasal steroid , inhaled steroid ) whitin 30 day prior day 0 . Use herbal medication dietary supplement within 7 day prior day 0 discretion investigator . Unwillingness refrain herbal medication dietary supplement within 30 day day 0 discretion investigator . Receipt vaccine within last 30 day prior day 0 plan vaccination within next 30 day day 0 . Evolving encephalopathy attributable another identifiable cause within 7 day administration previous dose vaccine . Known hypersensitivity component study vaccine . Current participation clinical trial participation ( whole study ) clinical trial previous 3 month prior day 0 . Inability adhere protocol , include plan move area . Family history congenital hereditary immunodeficiency ( first degree ) . Infection HIV , hepatitis B C. Any medical condition , opinion investigator , might interfere evaluation study objective . Clinically significant abnormal laboratory value discretion investigator . Person frequent contact child less 1 year age ( father , childcare worker , nurse , etc… ) residence household person know immunodeficiency .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>31 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Live nasal vaccine prevention pertussis</keyword>
</DOC>